Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Morgenstern

Showing results (111-120 of 148) with videos related to

Pageof 15
Sort By:
Mycopathologia|November 4, 2011
Toward developing a universal treatment for fungal disease using radioimmunotherapy targeting common fungal antigensR A Bryan, A J Guimaraes, S Hopcraft, et al.
Leukemia|June 8, 2007
Transcriptional regulation of parathyroid hormone-related protein promoter P2 by NF-kappaB in adult T-cell leukemia/lymphomaM V P Nadella, W P Dirksen, K S Nadella, et al.
Paediatrics & Child Health|October 27, 2023
Ensuring access to innovative therapies for children, adolescents, and young adults across Canada: The single patient study experienceGabriel Revon-Riviere, Leah C Young, Elizabeth A Stephenson, et al.
JCO Precision Oncology|August 1, 2025
Mucin 16-Directed Therapy in Pediatric Sarcomas: Case Evidence of Ubamatamab Efficacy in Epithelioid Sarcoma and Its Implications for Other Sarcoma SubtypesDenise M Connolly, Gabriel Revon-Rivière, Rose Chami, et al.
JCO Precision Oncology|March 2, 2022
Immune Checkpoint Inhibition as Single Therapy for Synchronous Cancers Exhibiting Hypermutation: An IRRDC StudyJacob J Henderson, Anirban Das, Daniel A Morgenstern, et al.
European Journal of Cancer (Oxford, England : 1990)|July 20, 2016
Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group databaseDaniel A Morgenstern, Wendy B London, Derek Stephens, et al.
Pediatric Blood & Cancer|November 28, 2018
The challenge of defining "ultra-high-risk" neuroblastomaDaniel A Morgenstern, Rochelle Bagatell, Susan L Cohn, et al.
Cell Reports|April 12, 2025
DNA damage response deficiency enhances neuroblastoma progression and sensitivity to combination PARP and ATR inhibitionMadeline N Hayes, Sarah Cohen-Gogo, Lynn Kee, et al.
Journal of Pediatric Hematology/Oncology|December 11, 2013
Toxicity and outcome of children and adolescents participating in phase I/II trials of novel anticancer drugs: the Royal Marsden experienceDaniel A Morgenstern, Darren Hargrave, Lynley V Marshall, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2014
Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) predicts outcome in patients with stage 4 disease: A study from the International Neuroblastoma Risk Group DatabaseDaniel A Morgenstern, Wendy B London, Derek Stephens, et al.
Pageof 15

Showing results (111-120 of 148) with videos related to

Sort By:
Pageof 15
Mycopathologia|November 4, 2011
Toward developing a universal treatment for fungal disease using radioimmunotherapy targeting common fungal antigensR A Bryan, A J Guimaraes, S Hopcraft, et al.
Leukemia|June 8, 2007
Transcriptional regulation of parathyroid hormone-related protein promoter P2 by NF-kappaB in adult T-cell leukemia/lymphomaM V P Nadella, W P Dirksen, K S Nadella, et al.
Paediatrics & Child Health|October 27, 2023
Ensuring access to innovative therapies for children, adolescents, and young adults across Canada: The single patient study experienceGabriel Revon-Riviere, Leah C Young, Elizabeth A Stephenson, et al.
JCO Precision Oncology|August 1, 2025
Mucin 16-Directed Therapy in Pediatric Sarcomas: Case Evidence of Ubamatamab Efficacy in Epithelioid Sarcoma and Its Implications for Other Sarcoma SubtypesDenise M Connolly, Gabriel Revon-Rivière, Rose Chami, et al.
JCO Precision Oncology|March 2, 2022
Immune Checkpoint Inhibition as Single Therapy for Synchronous Cancers Exhibiting Hypermutation: An IRRDC StudyJacob J Henderson, Anirban Das, Daniel A Morgenstern, et al.
European Journal of Cancer (Oxford, England : 1990)|July 20, 2016
Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group databaseDaniel A Morgenstern, Wendy B London, Derek Stephens, et al.
Pediatric Blood & Cancer|November 28, 2018
The challenge of defining "ultra-high-risk" neuroblastomaDaniel A Morgenstern, Rochelle Bagatell, Susan L Cohn, et al.
Cell Reports|April 12, 2025
DNA damage response deficiency enhances neuroblastoma progression and sensitivity to combination PARP and ATR inhibitionMadeline N Hayes, Sarah Cohen-Gogo, Lynn Kee, et al.
Journal of Pediatric Hematology/Oncology|December 11, 2013
Toxicity and outcome of children and adolescents participating in phase I/II trials of novel anticancer drugs: the Royal Marsden experienceDaniel A Morgenstern, Darren Hargrave, Lynley V Marshall, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2014
Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) predicts outcome in patients with stage 4 disease: A study from the International Neuroblastoma Risk Group DatabaseDaniel A Morgenstern, Wendy B London, Derek Stephens, et al.
Pageof 15